What To Expect From CME Group Stock?
CME Group’s stock (NYSE: CME) has gained 8% YTD, as compared to the 9% rise in the S&P500 over the same period. Further, at its current price of $182 per share, it is trading 12% below its fair value of $208 – Trefis’ estimate for CME Group’s valuation. The company outperformed the consensus estimates in the first quarter of 2023, with total revenues increasing by 7% y-o-y to $1.4 billion. It was primarily driven by a 5% improvement in clearing & transaction fees, followed by a 9% increase in market data & information services revenues. Notably, the clearing & transaction fees benefited from a 4% growth in the aggregate average daily volume (ADV), mainly driven by a 26% jump in the interest rates contracts. On the cost front, total expenses rose by 8% y-o-y, reducing the operating margin from 63.8% to 63.4%. However, the non-operating income increased from $57.2 million to $243.2 million, more than making up for higher expenses. Overall, the net income grew 24% y-o-y to $883.8 million.
The company’s top line grew 7% y-o-y to $5 billion in FY 2022, driven by a 10% improvement in clearing & transaction fees and a 6% increase in market data & information services revenues. The growth in clearing & transaction fees was driven by higher trading activity – aggregate ADV was up 19% y-o-y. That said, the non-operating income decreased from $728.4 million to $474.4 million in the year. It resulted in a net income of $2.7 billion – up 2% y-o-y.
Moving forward, we expect the higher trading volumes to continue in the subsequent quarters. Altogether, CME Group revenues are estimated to touch $5.36 billion in FY2023. Additionally, CME’s adjusted net income margin is likely to be around $3.1 billion in the year. This coupled with an annual EPS of $8.55 and a P/E multiple of just above 24x will lead to a valuation of $208.
What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.
| Returns | May 2023 MTD [1] |
2023 YTD [1] |
2017-23 Total [2] |
| CME Return | -2% | 8% | 58% |
| S&P 500 Return | 1% | 9% | 87% |
| Trefis Multi-Strategy Portfolio | 0% | 9% | 244% |
- Why Isn’t CME Group Stock Performance Reflecting Its Record Revenues, Improving Margins?
- Up 25% Since The Beginning of 2023, Where Is CME Group Stock Headed?
- Up 26% YTD, What’s Next For CME Group Stock?
- What To Expect From CME Group Stock?
- CME Group Stock To Top The Street Expectations In Q4
- What To Expect From CME Group Stock?
[1] Month-to-date and year-to-date as of 5/22/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates